Netherlands· NL-99d9943f8534
Praxbind 2,5 g/50 ml oplossing voor injectie/infusie
A idarucizumab product containing idarucizumab, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Idarucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC V03AB37 (idarucizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Idarucizumab · ATC V03AB37
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- IDARUCIZUMAB
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Netherlands (NL)
- ATC code
- V03AB37
- ATC class
- Idarucizumab
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1056
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FrancePRAXBIND 2,5 g/50 ml, solution injectable/pour perfusionBOEHRINGER INGELHEIM INTERNATIONAL
- BelgiumPraxbind 2.5 g/50 mlBoehringer Ingelheim International
- CanadaPRAXBINDBOEHRINGER INGELHEIM (CANADA) LTD LTEE
- SwitzerlandPraxbind 2.5 g, Injektions- bzw. InfusionslösungBoehringer Ingelheim (Schweiz) GmbH
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- United KingdomPraxbind 2.5g/50ml solution for infusion vialsBoehringer Ingelheim Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praxbind
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b355fb89-4374-4655-a369-70d07368b17c GET /v1/drugs/b355fb89-4374-4655-a369-70d07368b17c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie of infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/praxbind-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Idarucizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117131",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"POLYSORBAAT 20 (E 432)",
"SORBITOL (E 420)",
"WATER VOOR INJECTIE"
],
"substances": [
"IDARUCIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2015/11/20",
"procedure_number": "EMEA/H/C/003986",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1056",
"additional_monitoring": "N"
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.